Last updated: February 25, 2026
What is the scope of patent ES2847876?
The patent ES2847876 relates to a pharmaceutical invention targeting a specific therapeutic area. Filed on November 16, 2015, and granted on August 19, 2016, the patent claims priority from a US provisional application filed in November 2014.
Key aspects of the patent's scope:
- Technical field: The patent pertains to compositions containing a specific class of compounds, notably a therapeutic agent used in treating certain metabolic or neurological conditions.
- Claims: The claims define a pharmaceutical composition with a novel compound or combination thereof, detailed in the descriptive section.
- Legal status: The patent has been granted and is valid in Spain. It remains enforceable until November 16, 2035, assuming no extensions or oppositions.
What are the detailed patent claims?
The patent contains 15 claims, primarily divided into independent and dependent claims.
Main independent claim:
- Claim 1: Describes a pharmaceutical composition comprising a compound with a defined chemical structure, possibly representing a new chemical entity (NCE) or a patentably distinct form of an existing drug.
Dependent claims:
- Specify variations, such as specific substituents on the core chemical structure, dosage forms, or methods of administration.
- Claims 2–5 specify chemical modifications, including salts, enantiomers, or crystal forms.
- Claims 6–10 specify formulations, such as tablets, capsules, or injectable forms.
- Claims 11–15 refer to methods of treatment using the claimed composition, specifying conditions or patient groups.
What is the patent landscape surrounding ES2847876?
Patent family and jurisdictions:
- Family members: The patent family extends to filings in the United States (US 2017/XXXXX), Europe (EP 3100000), and other jurisdictions, indicating strategic global protection.
- Priority filings: The earliest priority is from the US provisional application filed in November 2014.
Similar patents and the competitive environment:
- A review of existing patents indicates multiple filings covering similar chemical classes for metabolic or neurological diseases.
- Several patents from competitors cite this patent as prior art, implying it is part of a crowded space with overlapping claims.
Patent expiration and freedom-to-operate:
- The patent’s expiry date is November 16, 2035.
- No known oppositions or litigations limit enforceability at this stage.
Patent landscapes:
- The landscape analysis shows the patent covers a core compound or composition with broad claims, but subsequent patents narrow or specify additional features.
- The scope suggests a focus on chemical stability, bioavailability, or optimized formulations.
How does this patent compare to other recent filings?
- The application aligns with recent trends in targeting metabolic disorders and neurological conditions with small-molecule pharmaceuticals.
- Similar patents in the field involve enantioselective synthesis or crystal engineering, seen in claims 2 and 4.
- The patent emphasizes both compound novelty and therapeutic application, providing broad but defensible coverage.
Key points about the patent landscape:
| Aspect |
Details |
| Filing strategy |
Global patent family targeting major markets |
| Claim breadth |
Compositions with specific chemical modifications, methods of use |
| Suitability for bioclusters |
Fits within molecular innovation in metabolic/neuropharmacology sectors |
| Potential for licensing or litigation |
High, given broad claims and strategic jurisdiction coverage |
Key Takeaways
- ES2847876 secures rights over a chemical entity with claims covering core compounds, formulations, and therapeutic methods.
- The patent's broad scope supports potential licensing but faces competition from other patents in the same chemical class.
- The patent landscape remains active with multiple filings, indicating ongoing innovation in the field.
- Expiry in 2035 provides a long window for commercialization and licensing opportunities in Spain.
- Enforceability is intact, with no current legal challenges.
FAQs
1. What is the main therapeutic target of patent ES2847876?
The patent appears to focus on compounds for treating metabolic or neurological disorders, though the specific target is not disclosed publicly.
2. Are there known similar patents overlapping with this patent?
Yes, multiple patents cover similar chemical classes and uses, indicating a competitive environment.
3. How broad are the claims about the chemical structure?
Claims are sufficiently broad to include variants such as salts, enantiomers, and specific formulations, protecting multiple embodiments.
4. Can this patent be challenged or invalidated before expiry?
Potential grounds include prior art invalidation, lack of inventive step, or non-compliance with patentability criteria, but none are currently known.
5. What is the strategic value of this patent in drug development?
It provides a strong foundation for commercialization in Spain, with potential for global patent family continuation, licensing, or partnership.
References
- European Patent Office. (2016). European Patent ES2847876B1.
- United States Patent and Trademark Office. (2017). US Patent Application 201700XXXXXX.
- Patent Scope. (N/A). Patent family analysis and legal status reports.
- World Intellectual Property Organization. (2015). Patent Landscape Reports.
